Cadila gets USFDA nod for its Potassium ER tablets

August 11, 2014 | Monday | News | By BioSpectrum Bureau

Cadila get USFDA nod for its Potassium ER tablets

The company currently has 94 approvals

Drug firm Zydus Cadila has received final approval from the US Food and Drug administration (USFDA) to market Potassium Citrate ER tablets used in the prevention of kidney stones.

"We have received final approval from the United States Food and Drug Administration (USFDA) to market Potassium Citrate ER tablets in the strengths of 5 mEq, 10 mEq and 15 mEq," company said in a statement.

The estimated sales in 2014 for Potassium Citrate ER tablets is $131.7 million, as per IMS, it added.

The group currently has 94 approvals and has so far filed 239 abbreviated new drug applications (ANDA).